UBS Sticks to Its Hold Rating for Blueprint Medicines (BPMC)

UBS analyst David Dai maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $129.00. The company’s shares closed yesterday at $128.10.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

According to TipRanks, Dai is an analyst with an average return of -23.8% and a 30.43% success rate. Dai covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Blueprint Medicines, and Kura Oncology.

In addition to UBS, Blueprint Medicines also received a Hold from Morgan Stanley’s Judah Frommer in a report issued today. However, on June 3, Robert W. Baird maintained a Buy rating on Blueprint Medicines (NASDAQ: BPMC).

Based on Blueprint Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $149.41 million and a net profit of $496 thousand. In comparison, last year the company earned a revenue of $96.12 million and had a net profit of $89.14 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.